13F HOLDINGS REPORT
SR ONE CAPITAL MANAGEMENT, LP
Quarter ended Q3 2025 · Filed November 12, 2025 · Accession 0001193125-25-277769
Total Value
$691.4M
Positions
12
Other Managers
0
Confidential Omitted
No
Holdings (12)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Arcellx, Inc. | ACLX | 2,346,630 | $192.7M | 27.86% |
| 2 | CRISPR Therapeutics AG | CRSP | 2,038,763 | $132.1M | 19.11% |
| 3 | Zenas BioPharma, Inc | ZBIO | 4,911,539 | $109.0M | 15.77% |
| 4 | Mineralys Therapeutics Inc. | MLYS | 2,113,933 | $80.2M | 11.59% |
| 5 | ORIC Pharmaceuticals, Inc. | ORIC | 4,514,929 | $54.2M | 7.84% |
| 6 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $49.1M | 7.11% |
| 7 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $40.3M | 5.83% |
| 8 | Oruka Therapeutics, Inc | ORKA | 430,330 | $8.3M | 1.20% |
| 9 | Alumis Inc. | ALMS | 1,959,896 | $7.8M | 1.13% |
| 10 | Nkarta, Inc. | NKTX | 3,333,333 | $6.9M | 1.00% |
| 11 | Oculis Holding AG | OCSAW | 322,500 | $5.7M | 0.82% |
| 12 | enGene Holdings Inc. | ENGNW | 747,750 | $5.1M | 0.74% |